Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG’s Treg-focused action as a potential breakthrough for Alopecia areata treatment. Latest Ratings for NKTR Date Firm Action From To Mar 2022 Oppenheimer Upgrades Perform Outperform Nov 2021 Benchmark Upgrades Hold Buy Nov 2021 SVB Leerink Maintains Market Perform View More Analyst Ratings for NKTR View the…

Read More